GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kolon Life Science 102940.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

12,450

-0.80%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩208.98bn

FY2016FY2025

Net income

₩24.96bn

FY2016FY2025

Free cash flow

−₩28.18bn

FY2016FY2025

Shareholders' equity

₩584.03bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩208.98bn₩161.39bn₩124.64bn₩161.58bn₩165.49bn₩129.41bn₩148.54bn₩132.68bn₩118.10bn₩158.28bn
Gross profit₩55.89bn₩16.87bn₩21.24bn₩37.14bn₩48.50bn₩18.90bn₩25.56bn₩10.73bn₩28.65bn₩48.60bn
Research and development₩13.91bn₩16.44bn₩14.89bn₩13.60bn₩14.33bn₩13.15bn₩18.49bn₩19.42bn₩13.71bn₩11.04bn
Operating income₩33.99bn—−₩27.55bn₩7.86bn−₩453.6m−₩37.81bn−₩28.75bn−₩52.03bn−₩5.54bn₩18.30bn
Net income₩24.96bn−₩93.09bn−₩30.73bn₩2.13bn−₩1.37bn−₩43.20bn−₩92.32bn−₩50.69bn−₩1.40bn₩12.67bn
Diluted earnings per share1,906.73-7,492.79-2,692.37186.93-120.61-3,789.00-8,098.41-4,446.37-184.631,110.58

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩914.41bn₩419.56bn₩309.44bn₩314.12bn₩234.66bn₩248.34bn₩278.29bn₩618.90bn₩716.80bn₩354.57bn
Cash and short-term investments—₩12.42bn₩7.48bn₩6.37bn₩27.91bn₩15.03bn₩20.91bn₩37.77bn₩78.83bn₩137.85bn
Total liabilities₩330.38bn₩270.23bn₩171.76bn₩146.39bn₩135.25bn₩190.38bn₩177.27bn₩172.76bn₩171.38bn₩94.78bn
Debt₩4.99bn₩126.60bn₩107.86bn₩73.92bn₩68.93bn₩77.03bn₩78.73bn₩65.07bn₩49.04bn₩60.98bn
Shareholders' equity₩584.03bn₩149.34bn₩137.67bn₩167.72bn₩99.41bn₩57.96bn₩101.02bn₩446.15bn₩545.41bn₩259.79bn
Shares outstanding13m12m11m11m11m11m11m11m8m11m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₩10.21bn−₩14.08bn−₩24.87bn−₩20.85bn−₩16.19bn−₩7.31bn−₩20.18bn−₩13.60bn−₩8.29bn₩28.11bn
Capital spending−₩38.39bn−₩8.73bn−₩10.24bn−₩6.31bn−₩4.41bn−₩2.74bn−₩30.78bn−₩42.44bn−₩29.98bn−₩16.14bn
Free cash flow−₩28.18bn−₩22.81bn−₩35.10bn−₩27.16bn−₩20.60bn−₩10.05bn−₩50.96bn−₩56.03bn−₩38.27bn₩11.97bn
Dividends paid————————−₩1.52bn−₩668.3m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩50.59bn₩49.66bn₩44.72bn₩66.48bn₩52.96bn₩44.83bn₩46.87bn₩35.92bn
Gross profit₩9.56bn₩12.79bn₩7.95bn₩28.26bn₩11.17bn₩10.79bn₩7.94bn₩2.22bn
Operating income−₩690.6m₩22.05bn—₩27.54bn₩766.2m₩122.1m−₩18.83bn−₩9.53bn
Net income−₩2.19bn₩20.85bn−₩9.58bn₩25.54bn−₩1.49bn₩10.48bn−₩16.74bn−₩12.49bn
Diluted earnings per share-166.961,592.60-731.512,055.93-119.65843.65-1,347.10-1,005.75
Cash from operations−₩19.02bn−₩5.89bn−₩8.90bn₩2.58bn₩14.98bn₩1.54bn−₩14.08bn−₩9.87bn
Capital spending−₩4.63bn−₩4.53bn−₩10.90bn−₩8.05bn−₩4.05bn−₩15.39bn−₩8.73bn−₩6.88bn
Free cash flow−₩23.65bn−₩10.42bn−₩19.79bn−₩5.47bn₩10.93bn−₩13.84bn−₩22.81bn−₩16.74bn
Total assets₩1.08trn₩1.15trn₩914.41bn₩642.14bn₩588.80bn₩601.96bn₩419.56bn₩342.58bn
Cash and short-term investments—————₩7.33bn₩12.42bn₩13.18bn
Debt——₩4.99bn₩14.86bn₩9.46bn₩120.91bn₩115.91bn₩101.72bn
Shareholders' equity₩696.93bn₩784.13bn₩584.03bn₩346.41bn₩276.14bn₩301.40bn₩149.34bn₩113.05bn

Financial ratios

Data as of 30 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross margin26.7%10.5%17.0%23.0%29.3%14.6%———
Operating margin16.3%—-22.1%4.9%-0.3%-29.2%-17.9%——
Net margin11.9%-57.7%-24.7%1.3%-0.8%-33.4%———
Return on equity4.3%-62.3%-22.3%1.3%-1.4%-74.5%———
Return on assets2.7%-22.2%-9.9%0.7%-0.6%-17.4%———
Free cash flow yield——————6.1%16.5%18.6%
Revenue growth29.5%29.5%-22.9%-2.4%27.9%-12.9%———
Earnings growth-126.8%203.0%-1540.3%-255.2%-96.8%-53.2%———
Current ratio0.64x0.49x0.82x1.01x1.03x0.69x———
Debt to equity0.01x0.77x0.78x0.41x0.63x1.23x———
Equity ratio63.9%35.6%44.5%53.4%42.4%23.3%———
Interest coverage4.37x—-4.70x2.11x-0.08x-6.85x———
R&D as a share of sales6.7%10.2%11.9%8.4%8.7%10.2%———
Buybacks as a share of market value——————0.0%-49.9%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue9.0%10.1%5.6%
Operating income62.9%—31.6%
Net income127.0%—41.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin19.6%20.0%20.9%20.7%
Net margin-18.4%-14.7%-14.8%-16.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings27.1-3.1-9.6146.6-358.6-7.7-2.2-16.8-571.470.5
Price to sales3.21.82.41.93.02.61.46.46.85.6

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 28 Dec 2016.

FY2017FY2016FY2015FY2014FY2013FY2012FY2011FY2009
Paid in the year133.33366.667133.33311.111416.6672.6462.5682.518
  • 3-for-2 split · 27 Dec 2017
  • 6-for-5 split · 27 Dec 2013
  • 21-for-20 split · 28 Dec 2011
  • 1.03-for-1 split · 29 Dec 2010
  • 1.02-for-1 split · 29 Dec 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.